DNA damaging agents in combination with tyrosine kinase...

Details DNA damaging agents in combination with tyrosine kinase... DNA damaging agents in combination with tyrosine kinase...

2006-07-04

2006-07-04

Lankford, Jr., Leon B. (Department: 1651)

Chemistry: molecular biology and microbiology

Treatment of micro-organisms or enzymes with electrical or...

C435S173400, C435S212000, C424S094500, C514S025000, C514S027000, C514S456000, C514S457000, C600S001000

Reexamination Certificate

active

07070968

ABSTRACT:
The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.

REFERENCES:
patent: 4667063 (1987-05-01), Ball
patent: 4764378 (1988-08-01), Keith et al.
patent: 4826853 (1989-05-01), Piwinski et al.
patent: 5073379 (1991-12-01), Klimesch et al.
patent: 5151423 (1992-09-01), Piwinski et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5262409 (1993-11-01), Margolis et al.
patent: 5416091 (1995-05-01), King
patent: 5464840 (1995-11-01), Ting et al.
patent: 5512293 (1996-04-01), Landrau et al.
patent: 5523095 (1996-06-01), Wilson et al.
patent: 5561117 (1996-10-01), Wong et al.
patent: 5595762 (1997-01-01), Derrieu et al.
patent: 5661152 (1997-08-01), Bishop et al.
patent: 5672611 (1997-09-01), Doll et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5684013 (1997-11-01), Afonso et al.
patent: 5696121 (1997-12-01), Bishop et al.
patent: 5700806 (1997-12-01), Doll et al.
patent: 5703090 (1997-12-01), Afonso et al.
patent: 5712280 (1998-01-01), Doll et al.
patent: 5714609 (1998-02-01), Doll et al.
patent: 5719148 (1998-02-01), Bishop et al.
patent: 5721236 (1998-02-01), Bishop et al.
patent: 5728703 (1998-03-01), Bishop et al.
patent: 5807853 (1998-09-01), Bishop et al.
patent: 5852034 (1998-12-01), Njoroge et al.
patent: 5858411 (1999-01-01), Nakagami et al.
patent: 5861395 (1999-01-01), Taveras et al.
patent: 5874442 (1999-02-01), Doll et al.
patent: 5877177 (1999-03-01), Taveras et al.
patent: 5925639 (1999-07-01), Doll et al.
patent: 5939416 (1999-08-01), Rane et al.
patent: 5945429 (1999-08-01), Taveras et al.
patent: 5958890 (1999-09-01), Rane et al.
patent: 5958939 (1999-09-01), Afonso et al.
patent: 5958940 (1999-09-01), Rane et al.
patent: 5965570 (1999-10-01), Cooper et al.
patent: 5972381 (1999-10-01), Sangekar et al.
patent: 5972598 (1999-10-01), Chaudhary et al.
patent: 5985879 (1999-11-01), Taveras et al.
patent: 6030982 (2000-02-01), Njoroge et al.
patent: 6040305 (2000-03-01), Taveras et al.
patent: 6071907 (2000-06-01), Njoroge et al.
patent: 6316462 (2001-11-01), Bishop et al.
patent: 6524832 (2003-02-01), Kufe et al.
patent: 0 214 092 (1987-03-01), None
patent: 0 270 818 (1988-06-01), None
patent: 0 341 860 (1989-11-01), None
patent: 0 396 083 (1990-11-01), None
patent: 0 495 454 (1992-07-01), None
patent: 0 856 315 (1995-08-01), None
patent: 1 560 406 (1976-10-01), None
patent: WO 92/11034 (1991-12-01), None
patent: WO 94/06916 (1994-03-01), None
patent: WO 95/10515 (1995-04-01), None
patent: WO 95/10516 (1995-04-01), None
patent: WO 95/15949 (1995-06-01), None
patent: WO 96/30018 (1996-10-01), None
patent: WO 96/30362 (1996-10-01), None
patent: WO 96/30363 (1996-10-01), None
patent: WO 96/31477 (1996-10-01), None
patent: WO 96/31478 (1996-10-01), None
patent: WO 97/23478 (1997-07-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 97/38664 (1997-10-01), None
patent: WO 97/38697 (1997-10-01), None
patent: WO 97/45412 (1997-12-01), None
patent: WO 98/00113 (1998-01-01), None
patent: WO 98/11091 (1998-03-01), None
patent: WO 98/35554 (1998-08-01), None
patent: WO 98/54966 (1998-12-01), None
patent: WO 99/31140 (1999-06-01), None
patent: WO 99/32118 (1999-07-01), None
Arteaga et al., “p185c-erbB-2signaling enhances cisplatin-induced cytotoxicity inhuman breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair,”Cancer Res., 54:3758-3765, 1994.
Chazin et al., “Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor,”Oncogene, 7(9):1859-1866, 1992.
Hancock et al., “A monclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines,”Cancer Res., 51:4575-4580, 1991.
Pietras et al., “Antibody to HER-2
eu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells,”Oncogene, 9:1829-1838, 1994.
“Cell differentiation inducer contains a DNA synthesis inhibitor and specified tyrosine kinase inhibitor,” Derwent Publ. Ltd., 9021: Apr. 1990; “Cell differentiation inducer,” Patent abstracts of Japan, 14(310): C-0736, Apr. 1990.
Abou-Shoer et al., “Flavonoids fromKoelreuteria henryiand other sources as protein-tyrosine kinase inhibitors,”J. Nat. Proc., 56:967-969,1993.
Akinaga et al., “Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C,”Cancer Chemotherapy Pharmol., 32:183-189, 1993.
Alexandropoulos et al., “v-Fps-Responsiveness in the Egr-1 Promoter is Mediated by Serum Response Elements,”Nucleic Acids Research, 20(9):2355-2359, 1992.
Al-Khodairy and Carr, “DNA repair mutants defining G2checkpoint pathways in Schizosaccharomyce pombe,”The EMBO Journal, 11:1343-1350, 1992.
Angel et al., “ThejunProto-Oncogene is Positively Autoregulated by its Product, Jun/AP-1,”Cell, 55:875-885, 1988.
Atherton-Fessler et al., “Mechanisms of p34cdc2 regulation,”Mol. Cell. Biol., 13:1675-1685, 1993.
Attar et al., “Expression Cloning of a Novel Zinc Finger Protein that Binds to the c-fos Serum Response Element,”Molecular and Cellular Biology, 12(5):2432-2443, 1992.
Barbet and Carr, “Fission yeast weel protein kinase is not required for DNA damage-dependent mitotic arrest,”Nature, 364:824-827, 1993.
Baumann et al., “Response of Xenografts of Human Malignant Gliomas and Squamous Cell Carcinomas to Fractionated Irradiation,”J. Radiatiion Oncology Biol. Phys., 23(4):803-809, 1992.
Beutler and Cerami, “Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator,”Ann. Rev. Biochem., 57:505-518, 1988.
Bhuyan et al., “Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells,”Cancer Res., 52:5687-5692, 1992.
Bonni et al., “Characterization of a pathway for ciliary neurotrophic factor signaling to the nucleus,”Science, 262:1575-1579, 1993.
Boothman et al., “Identification and Characterization of X-Ray-Induced Proteins in Human Cells,”Cancer Research, 49:2871-2878, 1989.
Brach et al. “Ionizing radiation induces expression and binding activity of the nuclear factor κB,”J. Clin. Invest., 88:691-695, 1991.
Buchdunger et al., “4,5-dianilinophthalimide: a new protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity,”Proc. Natl. Acad. Sci., USA, 91:2334-2338, 1994.
Budach et al., “The TCD50and Regrowth Delay Assay in Human Tumor Xenografts: Differences and Implications,”Int. J. Radiation Oncology Biol. Phys., 25, 259-268, 1993.
Cantley et al., “Oncogenes and signal transduction,”Cell, 64:281-302, 1991.
Carter et al., “Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes,”Proc. Natl. Acad. Sci., USA, 88:2745-2749, 1991.
Casillas et al., “Stimulation of B-cells via the membrane immunoglobulin receptor or with phorbol myroistate 13-acetate induces tyrosine phosphorylation and activation of a 42-kDa microtubule-associated protein-2 kinase,”J. Biol. Chem., 266:19088-19094, 1991.
Chan et al., “Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor,”Biochem. Biophys. Res. Comm., 193:1152-1158, 1993.
Chen et al., “Structure of malhamensilipin A, an inhibitor of protein tyrosine kinase, from the cultured chrysophyte poterioochromonas malhamensis,”J. Nat. Products, 57:524-527, 1994.
Crompton et al., “Staurosporine- and radiation-induced G2-phase cell cycle block are equally released by caffeine,”Radiation Res., 135(3):372-379, 1993.
Darzynkiewi

Affiliated with

Also associated with

Rating

DNA damaging agents in combination with tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA damaging agents in combination with tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA damaging agents in combination with tyrosine kinase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3525681